Patents Assigned to GMAX BIOPHARM LLC.
-
Publication number: 20230346932Abstract: Provided herein are a stable solution formulation of an ETAR antibody, and use thereof in treating, preventing, or alleviating one or more symptoms of pulmonary arterial hypertension or one or more symptoms of cancer of a reproductive organ.Type: ApplicationFiled: January 17, 2023Publication date: November 2, 2023Applicant: Gmax Biopharm LLC.Inventors: Cheng Zhang, Kesuo Fan, Yong Guo, Chenjiang Yao, Hua Zhang, Xiaofeng Wang, Shuqian Jing
-
Patent number: 11780916Abstract: Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.Type: GrantFiled: March 19, 2019Date of Patent: October 10, 2023Assignee: Gmax Biopharm LLCInventors: Xiaofeng Wang, Hua Zhang, Chenjiang Yao, Cheng Zhang, Shuqian Jing
-
Patent number: 11712470Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.Type: GrantFiled: November 18, 2020Date of Patent: August 1, 2023Assignee: GMAX BIOPHARM LLCInventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Min Wang, Xinxin Shi, Hao Pan, Shuqian Jing
-
Patent number: 11542336Abstract: Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.Type: GrantFiled: March 19, 2019Date of Patent: January 3, 2023Assignee: GMAX BIOPHARM LLCInventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Liangliang Bi, Shuqian Jing
-
Publication number: 20220411520Abstract: Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.Type: ApplicationFiled: September 16, 2020Publication date: December 29, 2022Applicant: GMAX BIOPHARM LLCInventors: Hua ZHANG, Xiaofeng WANG, Chenjiang YAO, Cheng ZHANG, Shuqian JING
-
Publication number: 20220265771Abstract: Provided is a fusion protein of an ETA antibody and a TGF-? Trap. Also provided is a pharmaceutical composition of the fusion protein of the ETA antibody and the TGF-? Trap. Further provided is a method for treating, preventing, or improving one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension, pulmonary fibrosis, or cardiovascular fibrosis by using the fusion protein of the ETA antibody and the TGF-? Trap.Type: ApplicationFiled: July 14, 2020Publication date: August 25, 2022Applicant: GMAX BIOPHARM LLCInventors: Cheng ZHANG, Chenjiang YAO, Hua ZHANG, Xiaofeng WANG, Shuqian JING
-
Publication number: 20210162045Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.Type: ApplicationFiled: November 18, 2020Publication date: June 3, 2021Applicant: GMAX BIOPHARM LLCInventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Min Wang, Xinxin Shi, Hao Pan, Shuqian Jing
-
Publication number: 20210163614Abstract: Provided herein are an apelin receptor (APJ) antibody and its fusion protein with Elabela. Also provided herein is a pharmaceutical composition of a fusion protein with APJ antibody and Elabela, and use thereof in treating, preventing, or alleviating one or more symptoms of pulmonary arterial hypertension, pulmonary hypertension or one or more symptoms of heart failure.Type: ApplicationFiled: June 13, 2019Publication date: June 3, 2021Applicant: GMAX BIOPHARM LLCInventors: Cheng Zhang, Lei Sun, Rongzhu Wang, Chenjiang Yao, Xiaofeng Wang, Hua Zhang, Shuqian Jing
-
Publication number: 20210122827Abstract: Provided herein are a glucagon receptor (GCGR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GCGR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of hyperglycemia, type 2 diabetes, metabolic syndrome or dyslipidemia.Type: ApplicationFiled: March 19, 2019Publication date: April 29, 2021Applicant: GMAX BIOPHARM LLCInventors: Cheng ZHANG, Hua ZHANG, Xiaofeng WANG, Chenjiang YAO, Yan JIANG, Liangliang BI, Shuqian JING
-
Publication number: 20210061904Abstract: Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.Type: ApplicationFiled: March 19, 2019Publication date: March 4, 2021Applicant: Gmax Biopharm LLCInventors: Xiaofeng WANG, Hua ZHANG, Chenjiang YAO, Cheng ZHANG, Shuqian JING
-
Patent number: 10869927Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.Type: GrantFiled: August 12, 2019Date of Patent: December 22, 2020Assignee: GMAX BIOPHARM LLCInventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Min Wang, Xinxin Shi, Hao Pan, Shuqian Jing
-
Patent number: 10485870Abstract: Disclosed is a stable pharmaceutical solution formulation of a GLP-1R antibody fusion protein, comprising a therapeutically effective amount of the GLP-1R antibody fusion protein, an amino acid, a surfactant and a buffer system. The final concentration of the amino acid is 1-500 mM, the final concentration of the surfactant is 0.01%-0.5%, and the pH value of the stable solution formulation is from 5.0 to 8.0. The stable solution formulation of the present invention can be used in the treatment of diabetes, obesity and conditions associated therewith.Type: GrantFiled: February 3, 2016Date of Patent: November 26, 2019Assignee: Gmax Biopharm LLC.Inventors: Cheng Zhang, Hua Zhang, Kesuo Fan, Yong Guo, Shuqian Jing
-
Patent number: 10376581Abstract: The present invention discloses an antibody specifically binding to a human endothelin receptor and uses thereof, where the antibody can inhibit the functions of the human endothelin receptor. The present invention includes the preparation, cloning, expression, and characterization of the antibody. The present invention can be used to effectively treat pulmonary arterial hypertension, a disease associated with pulmonary arterial hypertension, and a reproductive organ cancer in a human.Type: GrantFiled: July 22, 2016Date of Patent: August 13, 2019Assignee: Gmax Biopharm LLC.Inventors: Cheng Zhang, Hua Zhang, Xiaofeng Wang, Chenjiang Yao, Yan Jiang, Min Wang, Xinxin Shi, Hao Pan, Shuqian Jing
-
Patent number: 10059773Abstract: Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.Type: GrantFiled: August 1, 2014Date of Patent: August 28, 2018Assignee: GMAX BIOPHARM LLC.Inventors: Cheng Zhang, Shuqian Jing, Hua Zhang, Xiaofeng Wang, Chenjiang Yao